AAO 2024: New gene therapy shows promise for treatment of …
Oct 20, 2024 · New research unveiled today at the 128th annual meeting of the American Academy of Ophthalmology in Chicago reveals that a novel gene therapy may improve vision in individuals with severe vision loss due to retinitis pigmentosa, a progressive inherited retinal disease for which no cure exists.
Ophthalmology Times - Ophthalmology news, articles, and events
A team of researchers in China detail a case of Thelazia callipaeda infection in the right eye of a 41-year-old woman working in an office. The patient presented with persistent foreign body sensation, pruritus, and redness despite initial treatment with …
Johnson & Johnson launches TECNIS Odyssey IOL in US
Oct 1, 2024 · Johnson & Johnson is expanding the launch of its presbyopia-correcting intraocular lense (IOL), TECNIS Odyssey, in the US.. The TECNIS Odyssey IOL is a new full vision range IOL, built on the TECNIS platform from Johnson & Johnson, which according to the company provides two times better contrast in low lighting than PanOptix. 1 Peter Menziuso, company group chairman, Vision, Johnson & Johnson ...
AAO 2024: Long-term low-dose antiviral treatment benefits …
Oct 19, 2024 · Long-term, low-dose antiviral treatment reduces the risk for potentially vision-damaging bouts of inflammation and infection, as well as pain, which occur when shingles affect the eye, according to new research presented October 19 at the American Academy of Ophthalmology’s (AAO) annual meeting in Chicago.
FDA accepts NDA from Aldeyra Therapeutics for reproxalap for dry …
Nov 19, 2024 · The FDA has accepted the resubmitted new drug application (NDA) from Aldeyra Therapeutics for its first-in-class investigational candidate, topical ocular reproxalap for the treatment of signs and symptoms of dry eye disease.At the same time, Aldeyra is choosing to expand their option agreement with AbbVie, granting the manufacturer more cash to bring the drug to market. 1
ASCRS 2024: What advancements in Light Adjustable Lens …
Apr 10, 2024 · Neda Nikpoor, MD, spoke to Ophthalmology Times about her presentation on the Light Adjustable Lens during an ASCRS symposia on IOL calculations.. Video Transcript. Editor's note - The following transcript has been lightly edited for clarity.. Neda Nikpoor, MD: Hi, my name is Neda Nikpoor.I am a private practice doctor—a cornea, cataract, and refractive surgeon in Honolulu, Hawaii.
AAO 2024: Clinical updates on Neurotech's NT-501
Oct 18, 2024 · Thomas Aaberg Jr, MD sat down to discuss previous presentations by Neurotech at EURETINA and Retina Society as well as upcoming presentations on NT-501 at this year's American Academy of Ophthalmology meeting held in Chicago, Illinois.
Expanding the range of vision with monofocal IOLs
Sep 17, 2024 · Reviewed by Kamran M. Riaz, MD. During a recent Ophthalmology Times Case-Based Roundtable, Kamran M. Riaz, MD, discussed expanding the use of enhanced monofocal IOLs in clinical and surgical practice beyond their use in conventional cataract surgery.He discussed 3 cases of “out-of-the-box” treatments. Riaz is a clinical professor, Thelma Gaylord Endowed Chair in Ophthalmology, and vice ...
AAO 2024: Livionex reports positive end-of-phase 2 meeting with …
Oct 18, 2024 · According to the company, there are no FDA-approved pharmacological therapies for age-related cataracts. Its C-KAD eye drop, improves vision in patients with early-to-moderate cataracts, by penetrating the eye to reduce lens clouding, the main cause for cataracts.
Physicians sort out pros and cons of several new IOLs on the market
Nov 12, 2021 · Monofocal IOLs The monofocal category was expanded recently with 2 novel aspheric hydrophobic acrylic lenses—the TECNIS Eyhance (ICB00, Johnson + Johnson Vision) and the Clareon (Alcon). The Eyhance IOL has extended depth of focus (EDoF)-like qualities through the design of the central 1 mm of its optic. However, the Eyhance was not approved as an EDoF lens and surgeons cannot charge a ...